Cargando…
Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non‐small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial‐to‐mesenchymal transition (EMT) in disseminated or circula...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718027/ https://www.ncbi.nlm.nih.gov/pubmed/31350945 http://dx.doi.org/10.1111/1759-7714.13156 |
_version_ | 1783447666315755520 |
---|---|
author | Poh, Mau Ern Liam, Chong Kin Mun, Kein Seong Chai, Chee Shee Wong, Chee Kuan Tan, Jiunn Liang Loh, Thian Chee Chin, Ka Kiat |
author_facet | Poh, Mau Ern Liam, Chong Kin Mun, Kein Seong Chai, Chee Shee Wong, Chee Kuan Tan, Jiunn Liang Loh, Thian Chee Chin, Ka Kiat |
author_sort | Poh, Mau Ern |
collection | PubMed |
description | Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non‐small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial‐to‐mesenchymal transition (EMT) in disseminated or circulating NSCLC cells. Here, we describe the first case of EMT as the cause of recurrence and metastasis in a patient with resected stage IIB lung adenosquamous carcinoma after adjuvant chemotherapy. We review the literature and explore the possible mechanisms by which EMT occurs in disseminated tumor cells (DTC) or circulating tumor cells (CTC) in response to adjuvant chemotherapy (cisplatin) as a stressor. We also explore the possible therapeutic strategies to reverse EMT in patients with recurrence. In summary, although adjuvant cisplatin‐based chemotherapy in resected NSCLC does extend survival, it may lead to the adverse phenomenon of EMT in disseminated tumor cells (DTC) or circulating tumor cells (CTC) causing recurrence and metastasis. |
format | Online Article Text |
id | pubmed-6718027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-67180272019-09-06 Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy Poh, Mau Ern Liam, Chong Kin Mun, Kein Seong Chai, Chee Shee Wong, Chee Kuan Tan, Jiunn Liang Loh, Thian Chee Chin, Ka Kiat Thorac Cancer Case Reports Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non‐small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial‐to‐mesenchymal transition (EMT) in disseminated or circulating NSCLC cells. Here, we describe the first case of EMT as the cause of recurrence and metastasis in a patient with resected stage IIB lung adenosquamous carcinoma after adjuvant chemotherapy. We review the literature and explore the possible mechanisms by which EMT occurs in disseminated tumor cells (DTC) or circulating tumor cells (CTC) in response to adjuvant chemotherapy (cisplatin) as a stressor. We also explore the possible therapeutic strategies to reverse EMT in patients with recurrence. In summary, although adjuvant cisplatin‐based chemotherapy in resected NSCLC does extend survival, it may lead to the adverse phenomenon of EMT in disseminated tumor cells (DTC) or circulating tumor cells (CTC) causing recurrence and metastasis. John Wiley & Sons Australia, Ltd 2019-07-27 2019-09 /pmc/articles/PMC6718027/ /pubmed/31350945 http://dx.doi.org/10.1111/1759-7714.13156 Text en © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Poh, Mau Ern Liam, Chong Kin Mun, Kein Seong Chai, Chee Shee Wong, Chee Kuan Tan, Jiunn Liang Loh, Thian Chee Chin, Ka Kiat Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy |
title | Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy |
title_full | Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy |
title_fullStr | Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy |
title_full_unstemmed | Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy |
title_short | Epithelial‐to‐mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy |
title_sort | epithelial‐to‐mesenchymal transition (emt) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718027/ https://www.ncbi.nlm.nih.gov/pubmed/31350945 http://dx.doi.org/10.1111/1759-7714.13156 |
work_keys_str_mv | AT pohmauern epithelialtomesenchymaltransitionemttosarcomainrecurrentlungadenosquamouscarcinomafollowingadjuvantchemotherapy AT liamchongkin epithelialtomesenchymaltransitionemttosarcomainrecurrentlungadenosquamouscarcinomafollowingadjuvantchemotherapy AT munkeinseong epithelialtomesenchymaltransitionemttosarcomainrecurrentlungadenosquamouscarcinomafollowingadjuvantchemotherapy AT chaicheeshee epithelialtomesenchymaltransitionemttosarcomainrecurrentlungadenosquamouscarcinomafollowingadjuvantchemotherapy AT wongcheekuan epithelialtomesenchymaltransitionemttosarcomainrecurrentlungadenosquamouscarcinomafollowingadjuvantchemotherapy AT tanjiunnliang epithelialtomesenchymaltransitionemttosarcomainrecurrentlungadenosquamouscarcinomafollowingadjuvantchemotherapy AT lohthianchee epithelialtomesenchymaltransitionemttosarcomainrecurrentlungadenosquamouscarcinomafollowingadjuvantchemotherapy AT chinkakiat epithelialtomesenchymaltransitionemttosarcomainrecurrentlungadenosquamouscarcinomafollowingadjuvantchemotherapy |